Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159388 · ClinicalTrials.gov registry record · Phase 1
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
A Phase 1 study, sponsored by Servier Bio-Innovation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT05159388: Clinical Trial Phase 1 study, sponsored by Servier Bio-Innovation.
NCT05159388 is a Phase 1 study that was terminated before completion, run by Servier Bio-Innovation. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05159388, a Phase 1 study, was terminated before completion, sponsored by Servier Bio-Innovation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
Primary Outcome
Phase 1: Dose-limiting toxicities (DLTs) over the first 28-days of study treatment
Interventions
- DRUG PRS-344/S095012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Why NCT05159388 stopped before completion
NCT05159388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 1 intervention - of which PRS-344/S095012 is the first listed.
NCT05159388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05159388 about?
NCT05159388 is a clinical study titled "A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors". This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
What is the current status of trial NCT05159388?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-09-08. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT05159388?
The interventions under investigation include: PRS-344/S095012 (DRUG).
Who is sponsoring clinical trial NCT05159388?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05159388's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI